Your browser doesn't support javascript.
loading
Intravenous trimethylamine N-oxide infusion does not modify circulating markers of liver health, glucose tolerance, and milk production in early-lactation cows.
Myers, William A; Wang, Feiran; Chang, Crystal; Davis, Amanda N; Rico, J Eduardo; Tate, Brianna N; France, Tanya L; Wang, Linfeng F; McFadden, Joseph W.
Affiliation
  • Myers WA; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • Wang F; Department of Animal Science, Cornell University, Ithaca, NY 14853; China Agricultural University, Beijing, China 830052.
  • Chang C; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • Davis AN; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • Rico JE; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • Tate BN; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • France TL; Department of Animal Science, Cornell University, Ithaca, NY 14853.
  • Wang LF; Department of Animal Science, Cornell University, Ithaca, NY 14853; Henan Agricultural University, Zhengzhou, China 450046.
  • McFadden JW; Department of Animal Science, Cornell University, Ithaca, NY 14853. Electronic address: McFadden@cornell.edu.
J Dairy Sci ; 104(9): 9948-9955, 2021 Sep.
Article in En | MEDLINE | ID: mdl-34176629
ABSTRACT
In rodents and humans, the gut bacteria-derived metabolite trimethylamine N-oxide (TMAO) has been implicated in the progression of cardiovascular disease, chronic kidney disease, fatty liver, and insulin resistance; however, the effects of TMAO on dairy cattle health and milk production have not been defined. We aimed to determine whether intravenous TMAO infusion modifies measures of liver health, glucose tolerance, and milk production in early-lactation cows. Eight early-lactation Holstein cows (30.4 ± 6.41 d in milk; 2.88 ± 0.83 lactations) were enrolled in a study with a replicated 4 × 4 Latin square design. Cows were intravenously infused TMAO at 0 (control), 20, 40, or 60 g/d for 6 d. Washout periods lasted 9 d. Intravenous glucose tolerance tests (GTT) occurred on d 5. Blood was collected daily. Milk was collected on d -1, 0, 5, and 6. Urine was collected on d -1 and 6. Circulating metabolites, milk components, and TMAO concentrations in milk, urine, and plasma were quantified. Data were analyzed using a mixed model that included the fixed effects of treatment. Concentrations of TMAO in plasma, milk, and urine increased linearly with increasing dose. Dry matter intake and milk production were not modified by treatment. Daily plasma triacylglycerol, fatty acid (FA), and glucose concentrations were not modified. Serum albumin, total protein, globulin, total bilirubin, direct bilirubin, aspartate aminotransferase, γ-glutamyl transferase, and glutamate dehydrogenase concentrations were also not modified by treatment. Serum GTT glucose, FA, and insulin concentrations were not modified by treatment. Plasma total, reduced, and oxidized glutathione concentrations were also not modified by treatment. We conclude that a 6-d intravenous infusion of TMAO does not influence measures of liver health, glucose tolerance, or milk production in early-lactation dairy cows.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Milk / Diet Limits: Animals Language: En Journal: J Dairy Sci Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Milk / Diet Limits: Animals Language: En Journal: J Dairy Sci Year: 2021 Document type: Article